Novo Nordisk’s Fiasp approved for children with diabetes

Novo Nordisk’s Fiasp approved for children with diabetes
Credit: Shutterstock.com/ Syda Productions

Fiasp, an insulin aspart injection made by Denmark’s Novo Nordisk, has been approved in the US for use as a new mealtime insulin option for children with diabetes.

To date, Fiasp is the first and only fast-acting mealtime insulin injection that does not have a pre-meal dosing recommendation.

It is now available for use in children and adults in three different dosing options: multiple daily injections (MDI), continuous subcutaneous insulin infusion pumps and intravenous infusion under supervision by a healthcare professional.

The approval is based on the FDA’s review of data from the onset 7 clinical trial, which confirmed the efficacy and safety of Fiasp in children.